Exchange: NASDAQ·Updated 02:31 AM EDT

PACB News

News
all
press releases
The Wildest Catalyst Stories Hitting the Tape
Today’s session is packed with stories that can move quickly. Among the names attracting attention are Kraig Biocraft Laboratories (OTCQB:KBLB), Pacific Biosciences of California (NASDAQ:PACB), Tenon Medical (NASDAQ:TNON), Faraday Future Intelligent Electric (NASDAQ:FFAI), Creative Media & Community Trust Corporation (NASDAQ:CMCT), Lion Group Holding Ltd. (NASDAQ:LGHL), ImmunityBio, Inc. (NASDAQ:IBRX), Change Agents Corporation (NASDAQ:CHGA), Inventiva S.A. (NASDAQ:IVA), and Quantum-Si Incorporated (NASDAQ:QSI).
24-7 Market News
The Wildest Catalyst Stories Hitting the Tape
Today’s session is packed with stories that can move quickly. Among the names attracting attention are Kraig Biocraft Laboratories (OTCQB:KBLB), Pacific Biosciences of California (NASDAQ:PACB), Tenon Medical (NASDAQ:TNON), Faraday Future Intelligent Electric (NASDAQ:FFAI), Creative Media & Community Trust Corporation (NASDAQ:CMCT), Lion Group Holding Ltd. (NASDAQ:LGHL), ImmunityBio, Inc. (NASDAQ:IBRX), Change Agents Corporation (NASDAQ:CHGA), Inventiva S.A. (NASDAQ:IVA), and Quantum-Si Incorporated (NASDAQ:QSI).
24-7 Market News
More News
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Pacific Biosciences of California (PACB) closed at $1.62, marking a +2.53% move from the previous day.
Zacks
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indicating a +2.99% shift from the previous trading day.
Zacks
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Zacks
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
Zacks
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PacBio cut its 2026 revenue outlook as weaker instrument demand and a slower SPRQ-Nx transition raised the stakes for clinical adoption.
Zacks
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Zacks
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0.00% and -4.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
What's in Store for These 4 Healthcare Companies This Earnings Season?
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Zacks

Advertisement|Remove ads.